Researchers work to develop rapid cancer detection from a single drop of blood
Postdoctoral research fellow Dr Saimon Moraes Silva has been working with industry partner, Universal Biosensors, to develop a handheld device that can detect a cancer biomarker from a finger prick of blood.
In summary
- Swinburne researchers have been working with Universal Biosensors to develop technology to detect cancer from a single drop of blood
- The technology is a handheld electrochemical device, similar to the glucose meters used by diabetics
- The device could potentially be used by GPs and oncologists to test cancer patients in remission
- It is hoped the product can be brought to market within the next five years
Detecting and monitoring cancer through a simple finger prick blood test is the goal of a joint project between Swinburne and industry partner Universal Biosensors (UBI).
Using UBI’s electrochemical platform, Swinburne researchers have been working to develop a biosensor for the Tn antigen, a biomarker used for detecting, staging and monitoring cancer.
“The Tn antigen is a universal cancer biomarker because this molecule is present in more than 80 per cent of carcinomas,” says Swinburne’s Dr Saimon Moraes Silva. “You don’t see this molecule in healthy people.”
Dr Moraes Silva has been working on this project for three years under the supervision of Professor Simon Moulton from Swinburne’s School of Science, Computing and Engineering Technologies and Iverson Health Innovation Research Institute.
“The Tn technology has been developed through ARC Discovery grant funding and we are very excited to be working with UBI to translate this research into a commercial product that will have significant impact for cancer patients,” says Professor Moulton.
Swinburne has partnered with UBI to develop this technology, which is a handheld electrochemical device, similar to the glucose meters used by diabetics.
“We have developed a surface chemistry based on a molecule called lubricin,” says Dr Moraes Silva.
“Our device would only require a very tiny amount of blood – less than 20 microlitres. There is no need for sample preparation and you get an on the spot result.”
Ideally, he says, the devices could be used by GPs and oncologists to routinely test their cancer patients in remission.
Low limit of detection
Another advantage of this device is its extremely low limit of detection. “We can detect very low concentrations of the Tn antigen, in the range of 10-12 picomolar, which is a very low concentration,” Dr Moraes Silva says.
“We think there is the potential to also use it for early diagnosis because it could detect this Tn antigen even before a tumour starts to develop.”
Clinical testing on patients in Melbourne and in Europe are about to start and it is hoped the product can be brought to market within the next five years.
“To be able to identify and measure, then monitor the rate of a healthy human cell becoming a cancer cell from a handheld point-of-care biosensor device is an exciting prospect for UBI,” says CEO of UBI, John Sharman.
“It would be wonderful if this initiative could improve the lives of many of the 80 million carcinoma remission patients around the world.”
Swinburne and Deakin Institute of Frontier Materials will also work with UBI to fast-track the development of other biosensors, using UBI’s electrochemical platform technology.
Universal Biosensors was a pioneer in blood glucose meters. Founded in 2001, UBI, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare point of care, food and beverage and agriculture.
-
Media Enquiries
Related articles
-
- Design
- Astronomy
- Technology
- University
Swinburne ‘Rock Muncher’ takes part in Australian Rover Challenge
A multidisciplinary student team from Swinburne University of Technology competed in the 2024 Australian Rover Challenge held in Adelaide, South Australia.
Thursday 11 April 2024 -
- Technology
- Education
- University
From humble beginnings to global impact: what Quitch did next
Dr Grainne Oates transforms Quitch from startup to global powerhouse, redefining education with Swinburne's support.Friday 01 March 2024 -
- Health
Half of Australians living in aged care have depression – psychological therapy could help according to new research
An evaluation of more than 40 years of research has found that psychological therapy offers a promising alternative to the overreliance on anti-depressants in aged care.
Wednesday 20 March 2024 -
- Technology
CSIRO and Swinburne level up Australia’s manufacturing sector with Industry 4.0 Testlab
The Testlab has showcased its world-first fully automated industrial-scale production facility using a 3D-printing approach to composite component creation.
Read more (CSIRO and Swinburne level up Australia’s manufacturing sector with Industry 4.0 Testlab )Wednesday 13 March 2024 -
- Technology
World first project could see EVs charge wirelessly on the road
A $3 million grant by the Australian government will implement dynamic wireless charging technology into roads, unlocking the uptake of electric heavy vehicles and saving $324 billion by 2050.
Friday 16 February 2024